GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
Erola Pairo-Castineira,Konrad Rawlik,Andrew D Bretherick,Ting Qi,Yang Wu,Isar Nassiri,Glenn A McConkey,Marie Zechner,Lucija Klaric,Fiona Griffiths,Wilna Oosthuyzen,Athanasios Kousathanas,Anne Richmond,Jonathan Millar,Clark D Russell,Tomas Malinauskas,Ryan Thwaites,Kirstie Morrice,Sean Keating,David Maslove,Alistair Nichol,Malcolm G Semple,Julian Knight,Manu Shankar-Hari,Charlotte Summers,Charles Hinds,Peter Horby,Lowell Ling,Danny McAuley,Hugh Montgomery,Peter J M Openshaw,Colin Begg,Timothy Walsh,Albert Tenesa,Carlos Flores,José A Riancho,Augusto Rojas-Martinez,Pablo Lapunzina,GenOMICC Investigators,SCOURGE Consortium,ISARICC Investigators,23andMe COVID-19 Team,Jian Yang,Chris P Ponting,James F Wilson,Veronique Vitart,Malak Abedalthagafi,Andre D Luchessi,Esteban J Parra,Raquel Cruz,Angel Carracedo,Angie Fawkes,Lee Murphy,Kathy Rowan,Alexandre C Pereira,Andy Law,Benjamin Fairfax,Sara Clohisey Hendry,J Kenneth Baillie
DOI: https://doi.org/10.1038/s41586-023-06034-3
IF: 64.8
Nature
Abstract:Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte-macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).